baber/WOPTO huggingface dataset:
Patent NZ-573545-A (NZ)
Title: Modular storage unit for rack mount electronic devices allowing pivotal movement of each device
Inventor: VINCENT ROSS ALBERT
IPC: H05K7/14
Filed: 2007-06-13
Abstract: Disclosed is a storage unit for rack-mount electronic devices which includes an openable housing and a mounting system mounted within the housing for receiving and retaining one or more rack-mount electronic devices. The mounting system includes a hinging assembly with a chain of two or more hinging components which are interconnected for hinged movement relative to each other such that each pair of adjacent hinging components of the chain are pivotably coupled about a respective common pivot axis for hinged movement about that pivot axis. Two or more modular brackets each have an attachment part that is configured to releasably couple the bracket to one of the hinging components of the hinging assembly to support the bracket on the hinging assembly and allow hinged movement relative to each other. Each bracket is configured and dimensioned to releasably receive and retain one or more rack-mount electronic devices via slidable engagement of the device(s) into the bracket.
Patent NZ-575394-A (NZ)
Title: Compositions of chk1 inhibitors and cyclodextrin
Inventor: COLVIN ANITA A
IPC: C08L3/00
Filed: 2007-10-02
Abstract: Disclosed is a composition which comprises: (a) at least one substituted N-pyrazole-N'-phenyl-urea compound having a structural formula as represented by the formula (I) capable of inhibiting Chk1 and (b) at least one cyclodextrin; wherein in the compound of formula (I), R39 is halo, alkyl, cyano or CF3; R40 is hydrogen, alkyl, cyano, alkoxy, halo, or N(R45)2; R41 is a 6- or 7-membered saturated heterocyclic ring; R42 is hydrogen, alkyl, alkoxy, S-alkyl, N(R45)2, NR45C(=O)alkyl, or a 5- or 6-membered saturated heterocyclic ring containing one N-R44 group and optionally ring substituted with one to three alkyl groups; or R40 and R42 are taken together with the carbons to which they are attached to form a 5- to 7-membered saturated carbocyclic ring; R43 is hydrogen or halo; and wherein the other substituents are as defined herein, and wherein the composition is for the treatment of a disorder involving aberrantly proliferating cells such as cancer.
Patent NZ-578655-A (NZ)
Title: Calibration and normalization method for biosensors
Inventor: BUDACH WOLFGANG ERNST GUSTAV
IPC: C12Q1/00
Filed: 2008-03-21
Abstract: Disclosed is a method for assessing the immobilization quality and/or quantity of probes or an array of probes immobilized on a biosensor having a periodic grating structure and a multitude of probe locations on a surface thereof, wherein the immobilization quality and/or quantity of the immobilized probes is assessed individually at each probe location in a spatially resolved manner prior to the binding of an analyte to the probes, said method comprising the steps of: (1) obtaining two-dimensional data and/or images from said biosensor by: (A) in an Evanescent Resonance mode, exciting of bound luminescence labels bound to the probes and collecting data of the resulting emissions from said biosensor, and (B) in a label-free mode, obtaining a two dimensional image of the biosensor surface and peak wavelength value (PWV) data for the portions of the two-dimensional image which comprise images of probe locations of the biosensor, the peak wavelength value comprising the peak wavelength of light reflected from the biosensor due to resonant coupling of light into the biosensor; and (2) characterizing the immobilization quality and/or quantity of the probes or array of probes immobilized on the biosensor surface from the two-dimensional data and/or images.
Patent NZ-578874-A (NZ)
Title: Melon plants
Inventor: FONCELLE BRUNO
IPC: A23L29/20
Filed: 2009-08-05
Abstract: Provided is a Cucumis.melo plant that produces fruit, wherein said fruit comprises at maturity: a) at least 400 mg citric acid per 100 g fwt; b) pH of 4.2 to 5.6; and c) at least 5.0 g sugar per 100 g fwt, and wherein said C.melo plant comprises a low pH gene. A specific deposited plant (Accession Number NCIMB 41202) is also provided.
Patent NZ-579596-A (NZ)
Title: Dayflower flavonoid 3',5'-hydroxylase gene
Inventor: YUKI SHUNJI
IPC: A01H5/00
Filed: 2008-03-13
Abstract: Provided is a gene encoding a flavonoid 3',5'-hydroxylase of Commelina communis, which comprises a specified amino acid sequence or an amino acid sequence having at least 90% homology to the amino acid sequence. Further provided is a method for producing a flower colour-changed plant, which comprises transfecting a plant with the said gene and expressing the gene. The method is especially useful in manipulating colours of orchids.
Patent NZ-580060-A (NZ)
Title: A mode selector for an electric lock includes 2 differently sized bodies seperated by a resilient, substantially incompressible member
Inventor: CHANG JASON
IPC: E05B47/02
Filed: 2007-12-20
Abstract: A mode selector for an electronic lock comprises two differently sized bodies 2, 2' maintained a substantially fixed distance apart by a resilient, substantially incompressible member 1.
Patent NZ-581594-A (NZ)
Title: Aqueous sol containing colloidal silica-based particles having high axial ratio and high specific surface area
Inventor: PERSSON MICHAEL
IPC: D21H21/10
Filed: 2008-06-04
Abstract: Aqueous sol containing colloidal particles based on silica having an axial ratio of at least about 10 and specific surface area of at least about 600 m2/g is disclosed. Further the aqueous sol containing silica-based particles has an axial ratio of at least about 10 and S-value up to about 25%, wherein the silica-based particles are surface-modified. The disclosure further relates to a sol containing silica-based particles having a viscosity of at least 50 cP and silica content of at least about 3 % by weight, wherein the silica-based particles have a specific surface area of at least about 600 m2/g. The disclosure further relates to a process for producing the aqueous silica-based sol, a sol containing silica-based particles obtained by the process, use of the sol containing silica- based particles as a flocculating agent. The disclosure also relates to a process for producing paper in which the sol containing silica-based particles is used as a drainage and retention aid.
Patent NZ-586511-A (NZ)
Title: A panel comprising insulating foam core with recycled foam
Inventor: CAROLAN JAMES
IPC: B29C44/32
Filed: 2008-12-15
Abstract: An insulating panel comprises a first sheet 2 with trapezoidal formations 12 and a second sheet 3. There is an insulating core 4 comprising a main polymeric foam body 4, such as of polyisocyansurate or phenolic foam, and a recycled foam portion. The recycled foam portion is of substantially the same formulation as that of the main foam body. Shredded foam pieces 25 are directly incorporated into the panel, for example into one or more of the profiled recesses 12 defined by crowns in the sheet 2The recycled foam portion is introduced prior to lay-down of liquid foam reactants to ensure that the recycled foam portion is integrated into the main foam body.
Patent NZ-589793-A (NZ)
Title: Nozzle configuration of nasal cushion for respiratory assistance mask
Inventor: GUNARATNAM MICHAEL KASSIPILLAI
IPC: A61M16/08
Filed: 2004-02-20
Abstract: A cushion 18 for a nasal breathing apparatus has a common base 48 with a side wall 52 and a central wall 54, and a pair of nozzles extending from the central wall. Each nozzle has a first portion 56 in the form of a hollow stalk having a first end extending from the central wall and a second end supporting a second portion in the form of a head portion 50 having a hollow structure approximating the shape of a truncated cone. Pressurized gas may travel from inside the central wall through the stalks and to openings in the head portions for delivery to the patient's nostril openings. The entire wall 56 of each stalk extending from the central wall to the bottom of the head portion is a single concave curve in cross section.
Patent NZ-594303-A (NZ)
Title: Rigless abandonment system
Inventor: DESAI PRAFUL C
IPC: E21B33/13
Filed: 2009-12-30
Abstract: 594303 A rigless abandonment system including a surface vessel (2) having an attached lifting device (6) and a moonpool (8). The system further includes a cutting module (10) configured to connect to a subsea wellhead (4), the cutting module having a wellhead connector having an actuatable lock and release mechanism, a motor assembly, and a cutter. An umbilical line connects the cutting module to the surface vessel, wherein the lifting device is used to raise and lower the cutting module connected to the surface vessel through the moonpool. A method for performing rigless casing cutting and wellhead removal operations, the method includes positioning a surface vessel above a subsea wellhead, where the surface vessel has a moonpool and a lifting device. The method further includes providing a cutting module, and deploying the cutting module through the moonpool, wherein the cutting module is connected to the surface vessel by an umbilical line.
Patent NZ-595273-A (NZ)
Title: Regeneration of pancreatic islets and reversal of diabetes by islet transcription factor genes delivered in vivo
Inventor: GRAYBURN PAUL A
IPC: C12N5/071
Filed: 2009-11-13
Abstract: Disclosed is a composition for ultrasound-targeted microbubble destruction in the pancreas comprising: a pre-assembled liposome-nucleic acid microbubble complex comprising a nucleic acid; the nucleic acid characterized in that it comprises one or more insulin responsive regulatory genes operatively linked to an insulin promoter, the insulin promotor characterized in that it comprises a genomic fragment comprising a 5' untranslated region of exon1, intron1, and exon2 of the insulin gene, wherein the one or more insulin responsive regulatory genes comprise GLP1; wherein disruption of the microbubble in the pancreas at a target site delivers the nucleic acid into pancreas cells at the location of the ultrasound disruption, wherein cells that incorporate the nucleic acid express insulin in response to high blood glucose levels.
Patent NZ-595460-A (NZ)
Title: Method for filling food containers
Inventor: ULLMANN BERND
IPC: B21D51/26
Filed: 2010-05-12
Abstract: The disclosure relates to a method for filling thin-walled food containers (14), in particular beverage cans, which as a result are sealed gas-tight and have a internal pressure lying above the ambient pressure to stabilize the food container. The method comprises the following method steps: providing a food container having an open filling opening in a filling station (10), filling the food container in the filling station, covering the filling opening of the food container using a lid immediately after the filling has been concluded, fixing the lid on the food container without sealing the food container gas-tight, transporting away the food container having the covered filling opening.
Patent NZ-596168-A (NZ)
Title: Use of delta-tocopheryl-carbohydrate as a depigmenting agent
Inventor: POIGNY STEPHANE
IPC: A61K8/34
Filed: 2010-05-12
Abstract: 596168 Disclosed herein is a depigmenting cosmetic composition wherein the composition contains, in a dermo-cosmetically acceptable vehicle, from 0.05% to 1% by weight of the delta-tocopheryl-carbohydrate of Formula I. In one embodiment, the composition includes at least one other depigmenting agent selected among hydroxylated diphenylmethane derivatives, retinoids, Rucinol, kojic acid, linoleic acid and a plant oil rich in linoleic acid in triglycerate form, or a mixture of these.
Patent NZ-596366-A (NZ)
Title: Enhanced immune response in avian species
Inventor: ABRAHAM ALBERT
IPC: A61K39/00
Filed: 2010-05-07
Abstract: Patent No. 596366 Disclosed is a method for eliciting a non-antigen specific immune response in a member of the avian species, comprising administering, in-ovo or by spray, an effective amount of an immunomodulator composition to the avian species, wherein the immunomodulator composition comprises: a. a cationic liposome delivery vehicle; and b. a bacterially-derived nucleic acid vector that does not code for an immunogen.
Patent NZ-597222-A (NZ)
Title: Substituted 8-[6-Amino-3-Pyridyl]Xanthines
Inventor: WANG GUOQUAN
IPC: A61K31/497
Filed: 2007-06-13
Abstract: Disclosed herein are 1-cyclopropyl substituted 8-[6-amino-3-pyridyl]xanthines of the given general formula, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as selective antagonists of A2B adenosine receptors (ARs) and as such are useful in the treatment allergy, allergic diseases, an autoimmune disease, diarrheal disease, insulin resistance, diabetes, cancer, an ischemia/reprefusion injury, diabetic retinopathy or hyperbaric oxygen-induced retinopathy. Examples of particularly preferred compounds include: 1-Cyclopropyl-3-propyl-8-[6-(N-[6-(trifluoromethyl)nicotinoyl]-N-methylamino)-3-pyridyl]xanthine; 1-CyclopropyI-3-propyl-8-[6-(N-[6-(trifluoromethyl)nicotinoyI]-N-propylamino)-3-pyridyl]xanthine; 1-Cyclopropyl-3-propyl-8-[6-(N-[6-(trifluoromethyl)nicotinoyl]-N-(2-methoxyethyl)amino)-3-pyridyl]xanthirie; 1-Cyclopropyl-3-propyl-8-[6-(N-[6-fluoronicotinoyl]-N-[cyclopropylmethyl]amino )-3-pyridyl]xanthine; 1-Cyclopropyl-3-propyl-8-[6-(N-[6-(trifluoromethyl)nicotinoyl]-N-(2-[piperidin-1-yl]ethyl)amino)-3-pyridyl]xanthine; 1-Cyclopropyl-3-propyl-8-[6-(3-[trifluoro-m-tolyl)-1-(2,3-dihydroxypropyl]ureido)-3-pyridyl]xanthine.
Patent NZ-597468-A (NZ)
Title: Pulmonary surfactant formulations and methods for promoting mucus clearance
Inventor: JOHNSON MARK E
IPC: A61K38/16
Filed: 2007-09-19
Abstract: NZ 597468 Disclosed is the use of a pulmonary surfactant comprising one or more phospholipids and a polypeptide, in which the polypeptide, when admixed with a phospholipid, forms a synthetic pulmonary surfactant having a surfactant activity greater than the surfactant activity of the phospholipid alone and at least one osmotically active agent in the manufacture of a medicament for promoting mucus clearance in a patient with a pulmonary condition characterised by excessive mucus secretion or impaired mucus clearance, wherein the pulmonary condition is cystic fibrosis, bronchiectasis, primary or secondary ciliary diskinesia, COPD, or sinusitis and, wherein the synthetic pulmonary surfactant is formulated to provide the patient with a lung dose of between about 20 and 200mg total phospholipid equivalent per day and wherein the synthetic pulmonary surfactant comprises one or more pharmaceutically acceptable phospholipids admixed with an SP-B polypeptide or fragment thereof, or a polypeptide comprising at least 10 amino acid residues and no more than about 60 amino acid residues, said polypeptide including a sequence having alternating hydrophobic and hydrophilic amino acid residue regions represented by the formula: (ZaUb)cZd, wherein: Z is a hydrophilic amino acid residue independently selected from the group consisting of R and K; U is a hydrophobic amino acid residue independently selected from the group consisting of L and C; a is 1 or 2; b has an average value of about 3 to about 8; c is 1 to 10; and d is 0 to 2.
Patent NZ-600400-A (NZ)
Title: Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
Inventor: GARDNER JOSEPH H
IPC: A61K31/44
Filed: 2010-11-05
Abstract: Disclosed herein are methods for controlling the activity of hypoxia- inducible transcription factor I -alpha (HIFla) and diseases, conditions, or syndromes related thereto, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. Further disclosed are phannaceutical compositions comprising HIF- la prolyl hydroxylase inhibitors useful in treating diseases, conditions, and/or syndromes related thereto the activity of HIF -I a. Compounds used in the disclosed compositions and methods include: 1-Benzyl-3-hydroxy-4-[ 4-(2-methoxyphenyl)piperazin-1-ylmethyl]pyridin-2( 1H)-one; 1-Benzyl-3 -hydroxy-4-(thiazolidin-3-ylmethyl)pyridin-2( 1H)-one; 1-Benzyl-3-hydroxy-4-(piperidin-1-ylmethyl)pyridin-2(1H)-one and 1-(4’ -Methylbenzenesulfonyl)-3-hydroxy-4-[(2-methoxyethylamino)methyl]-pyridin-2(1H)-one.
Patent NZ-600711-A (NZ)
Title: Transgenic non-human animal and uses thereof
Inventor: DRESSLER HOLLY
IPC: A01K67/027
Filed: 2010-12-17
Abstract: Disclosed are transgenic non-human animal having a genome comprising a transgene construct comprising a first insulator element, a response element, a promoter, a bioluminescent reporter, a human growth hormone (hGH) functional element, and a second insulator element, wherein the first insulator element and the second insulator element are different.
Patent NZ-600785-A (NZ)
Title: Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents
Inventor: GAGLIARDI STEFANIA
IPC: A01N43/42
Filed: 2010-12-28
Abstract: 600785 Disclosed is the use of 8-hydroxy-quinoline-7-carboxamide derivatives as represented by the general formula (I), wherein A is: -(CH2)m-X1, -(CH2)m-cycloalkyl, -(CH2)m-W-X2, -(CH2)m-W-CH2-X1, or -(CH2)m-CHR9-(CH2)m-X1; wherein X1 is: aryl (optionally substituted by one, two or three R4), heterocycle (optionally substituted by one or two R5), alkyl, -CH(OH)-phenyl, -S-phenyl, -NHSO2-phenyl, -CN, -OH, cycloalkyl or 4-cyano-2,3,4,5-tetrafluoro-phenyl; wherein X2 is: aryl, heterocycle, alkyl, CH(OH)-phenyl, or cycloalkyl; wherein m is an integer from 0 to 6; and wherein the remaining substituents are as defined herein, in the manufacture of a medicament for the treatment and/or prevention of one or more fungal infections. Representative compounds include 8-hydroxy-N-(thiophen-2-ylmethyl)quinoline-7-carboxamide, 8-hydroxy-N-benzyl-quinoline-7-carboxamide, 8-hydroxy-N-(4-methoxyphenyl)quinoline-7-carboxamide, 8-hydroxy-N-(furan-2-ylmethyl)quinoline-7-carboxamide, 8-hydroxy-N-(1,1-dioxidotetrahydrothien-3-yl)quinoline-7-carboxamide, 8-hydroxy-N-(tetrahydro-2H-pyran-4-yl)quinoline-7-carboxamide, 8-hydroxy-N-(4-morpholinophenyl)quinoline-7-carboxamide, 8-hydroxy-N-(4-(1H-1,2,4-triazol-1-yl)phenyl)quinoline-7-carboxamide, 8-hydroxy-N-(thiazol-2-yl)quinoline-7-carboxamide, 8-hydroxy-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)quinoline-7-carboxamide and 8-hydroxy-N-(pyridin-2-ylmethyl)quinoline-7-carboxamide.
Patent NZ-602405-A (NZ)
Title: A fluid composition comprising a hyaluronan polymer and mannitol for improving skin conditions
Inventor: LEBRETON PIERRE
IPC: C08L5/08
Filed: 2010-05-10
Abstract: Disclosed is a dermal filler composition comprising: a) a hyaluronan polymer, consisting essentially of uncrosslinked hyaluronic acid having a mean molecular weight of at least about 2500000 Da, the uncrosslinked hyaluronan polymer being at least 95% by weight of the total hyaluronan polymer present in the composition; and b) mannitol present at about 0.5% (w/v) to about 5% (w/v) of the composition; wherein the composition has a dynamic viscosity of about 50 Pa•s to about 150 Pa•s (500P - 1500P). Also disclosed is an injectable dermal filler composition for rehydrating skin, the composition comprising; a) a hyaluronan polymer consisting essentially of hyaluronic acid having a mean molecular weight of at least 2,500,000 Da, wherein the hyaluronan polymer is present at a concentration of about 11.5 mg/mL to about 15.5 mg/mL, and wherein the composition is essentially free of crosslinked hyaluronan polymer; and b) mannitol present at about 0.5% (w/v) to about 5% (w/v) of the composition. Further disclosed is a method of making a dermal filler composition, the method comprising the steps of: a) combining mannitol with a physiologically-acceptable buffer to make a mannitol-buffered solution, wherein the mannitol is present at about 0.5% (w/v) to about 5% (w/v) of the solution; b) combining a hyaluronan polymer consisting essentially of uncrosslinked hyaluronic acid having a mean molecular weight of at least 2,500,000 Da, the uncross-linked hyaluronan polymer being at least 95% by weight of the total hyaluronan polymer, with the mannitol-buffered solution to hydrate the hyaluronan polymer, wherein the hyaluronan polymer is present at a concentration of about 11.5 mg/mL to about 15.5 mg/mL, and; c) sizing the fluid composition by recirculating the dermal filler composition between a first vessel and a second vessel through a narrow aperture; wherein the dermal filler composition has a dynamic viscosity of about 50 Pa•s to about 150 Pa•s.
Patent NZ-603953-A (NZ)
Title: Apparatus and method for analysing events from sensor data by optimization
Inventor: MASHINCHI MOHAMMAD HADI
IPC: G08B23/00
Filed: 2011-06-16
Abstract: Disclosed is a method for processing sensor signals representing one or more wetness events in an absorbent article. The method includes receiving sensor signals representing one or more wetness events in an absorbent article; and processing the sensor signals to determine a wetness event characteristic of at least one of the wetness events in the absorbent article. The method includes identifying automatically a sensor signal that is representative of each individual wetness event and, from the sensor signals representative of each individual wetness event: (i) generating a representative vector for that wetness event including one or more elements which include values derived from the sensor signals for that event; (ii) normalizing the elements of the representative vector; (iii) allocating weightings to the normalized elements of the representative vector to generate a weighted representative vector for that wetness event; and (iv) comparing the weighted representative vector with clusters of weighted representative vectors to determine which one or more of the clusters the weighted representative vector is most similar to and allocating a wetness event characteristic of the one or more clusters to the weighted representative vector for that wetness event. The wetness event characteristic indicates volume of exudate in that wetness event.
Patent NZ-608070-A (NZ)
Title: 2’-fluoro substituted carba-nucleoside analogs for antiviral treatment
Inventor: KIM CHOUNG
IPC: C07H19/00
Filed: 2011-03-22
Abstract: The disclosure relates to a family of compounds that fall within general Formula IV. These are modified nucleosides and nucleoside phosphates that contain an imidazo[1,2-f][1,2,4]triazinyl moiety. The 2’ position of the cyclic nucleoside sugar (which has a tetrahydrofuran structure) is substituted with halogen (R1) and carbon substituents (R2). R7 may be substituted with phosphate groups which may optionally also bind to the sugar via R3 or R5. The compounds are useful for the treatment of virus infections, particularly hepatitis C infections caused by both wild type and mutant strains of HCV. The disclosure also describes pharmaceutical compositions containing these compounds and methods to use them.
Patent NZ-615733-A (NZ)
Title: Process for the manufacture of non-steroidal anti-inflammatory agents and intermediates thereof
Inventor: SCHWEIZER DR STEFFEN
IPC: C07D405/08
Filed: 2008-04-17
Abstract: The disclosure relates to a chiral synthetic routes and intermediates for the manufacture of chiral anti-inflammatory agents which are enantiomerically pure form of substituted benzofuran derivatives represented by general formula (VIII) in which at least one of the groups X1, X2, X3 is selected from fluoro, chloro, bromo, hydroxy, methoxy, ethoxy, trifluoromethyl, amino whereas the other groups X1, X2, X3 have the meaning of a hydrogen atom, in which at least one of the groups Z1, Z2, Z3 is selected from -O-, -S-, -NH-, -N(-CH3)-, whereas the other groups Z1, Z2, Z3 have the meaning of a -CH2- group, and in which Ar is an aromatic group, wherein the enantiomeric purity of these compounds is greater than 80%.